快速降解的康雅克葡萄康曼南水凝与奥萨拉交叉连接,用于结肠药物释放
Qiao Zhang1, Huili Fu1, Yunfei Zhang1
1School of Materials Science and Engineering, Wuhan Institute of Technology, Wuhan, China.
Bio-medical materials and engineering
|September 18, 2023
概括
一种新型的konjac glucomannan (KGM) 水凝在结肠中迅速降解,改善药物释放. 这种亚交联的KGM水凝显示出针对性结肠药物输送系统的巨大潜力.
科学领域:
- 生物材料科学 生物材料科学
- 药物输送系统 药物输送系统
- 聚合物化学 聚合物化学
背景情况:
- 聚糖化水凝对于结肠药物输送至关重要.
- 目前的水凝降解太慢,无法有效释放结肠药物.
- 这导致药物在释放之前过早排放.
研究的目的:
- 开发一种快速降解的康杰克葡萄甘 (KGM) 水凝,用于结肠向药物释放.
- 为了使水凝的降解速度与其结肠保留时间相匹配.
- 通过控制药物输送来提高治疗疗效.
主要方法:
- 准备的KGM水凝使用olsalazine,一个含有亚键的交叉连接剂.
- 在正常缓冲体和人类便中研究了水凝降解.
- 在不同交叉连接密度下评估了5-甲 (5-Fu) 的药物释放动力学.
主要成果:
- 超过50%的KGM水凝重量在48小时内降解在5%的人类便中.
- 在相同的条件下,超过60%的5-fluorouracil (5-Fu) 被释放出来.
- 药物释放在模拟结肠环境中更快,与水凝降解相关.
结论:
- 亚交联KGM水凝提供了适合结肠输送的快速降解.
- 开发的水凝系统有效地控制了基于降解的药物释放.
- 这种KGM水凝对有针对性的结肠药物递送应用具有显著的前景.
更多相关视频
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
168
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
168
Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents
245
Diarrhea is characterized by the occurrence of frequent, watery bowel movements. Various factors can trigger diarrhea, including viral or bacterial infections, foodborne illnesses, side effects from certain medications, and underlying digestive disorders. If not adequately managed, diarrhea can lead to complications such as dehydration, electrolyte imbalances, and nutrient deficiencies. Severe diarrhea can lead to significant weight loss, malnutrition, and weakened immune function.
Adsorbents...
Adsorbents...
245
Drugs Affecting GI Tract Motility: Other Laxatives
264
Laxatives are primarily used to alleviate constipation, a common gastrointestinal disorder characterized by infrequent bowel movements and difficulty passing stools. They work by various mechanisms to increase the volume or frequency of bowel movements. The primary modes of action of laxatives include increasing stool bulk, softening the stool, stimulating intestinal motility, and osmotically drawing water into the intestines.
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
264
Drugs for Treatment of Constipation-Predominant IBS
201
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
201
Factors Affecting Dissolution: Drug Permeability, Stability and Stereochemistry
229
Orally administered drugs primarily enter the systemic circulation via passive diffusion through the intestinal membranes. The drug's absorption is influenced by drug stability in the gastrointestinal GI tract, membrane permeability, the surface area available for absorption, luminal drug concentration, and residence time in the lumen. Drug permeability can be enhanced by adjusting the lipophilicity, polarity, or molecular size of the drug, promoting its passive transport across intestinal...
229
Drugs for Treatment of Diarrhea-Predominant IBS
204
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
204


